



Claims:

1. A compound of the Formula



and solvates, tautomers, and pharmaceutically acceptable salts thereof, wherein:

Y is


, 
or 
;

R^1, R^3 and R^4 are each hydrogen;

R^2 is selected from H, OR^6, NR^6R^7, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 heteroalkyl, C_3-C_6 cycloalkyl, C_3-C_6 cycloalkenyl, heterocycloalkyl with 3 to 8 ring atoms wherein one atom is selected from nitrogen, oxygen and sulfur, aryl which is selected from the group consisting of phenyl, biphenyl, 1,2,3,4-tetrhydronaphthyl and naphthyl, and 5-7 membered heteroaryl, wherein said alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted with one or more groups independently selected from C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, F, Cl, Br, I, CN, OR^6, NR^6R^7, $C(=O)R^6$, $C(=O)OR^6$, $OC(=O)R^6$, $C(=O)NR^6R^7$, (C_1-C_6 alkyl)amino, CH_3OCH_2O-, $R^6OC(=O)CH=CH$-, $NR^6SO_2R^7$, SR^6 and SO_2R^6;

R^{5a}, R^{5b}, and R^{5c} are each hydrogen; and

R^6 and R^7 are independently selected from H, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C6 heteroalkyl, C_3-C_6 cycloalkyl, C_3-C_6 cycloalkenyl, heterocycloalkyl with 3 to 8 ring atoms wherein one atom is selected from nitrogen, oxygen and sulfur, aryl which is selected from the group consisting of phenyl, biphenyl, 1,2,3,4-tetrhydronaphthyl and naphthyl, and 5-7 membered heteroaryl, wherein said alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted with one or more groups

independently selected from C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, F, Cl, Br, I, CN, OR^6, NR^6R^7, $C(=O)R^6$, $C(=O)OR^6$, $OC(=O)R^6$, $C(=O)NR^6R^7$, (C_1-C_6 alkyl)amino, CH_3OCH_2O-, $R^6OC(=O)CH=CH$-, $NR^6SO_2R^7$, SR^6 and SO_2R^6,

or R^6 and R^7 together with the atom to which they are attached form a saturated or partially unsaturated heterocyclic ring with 3 to 8 ring atoms wherein one atom is selected from nitrogen, oxygen and sulfur, wherein said heterocyclic ring is optionally substituted with one or more groups independently selected from C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, F, Cl, Br, I, CN, OR^6, NR^6R^7, $C(=O)R^6$, $C(=O)OR^6$, $OC(=O)R^6$, $C(=O)NR^6R^7$, (C_1-C_6 alkyl)amino, CH_3OCH_2O-, $R^6OC(=O)CH=CH$-, $NR^6SO_2R^7$, SR^6 and SO_2R^6.

2. The compound of claim 1, wherein R^2 is OR^6.

3. The compound of claim 2, wherein R^6 is C_1-C_6 alkyl.

4. The compound of claim 3, wherein R^6 is ethyl.

5. The compound of claim 1, wherein R^2 is NR^6R^7.

6. The compound of claim 5, wherein R^6 and R^7 are independently H, C_1-C_6 alkyl or C_1-C_6 heteroalkyl.

7. The compound of claim 6, wherein R^6 and R^7 are independently H, ethyl, propyl, or $CH_2CH_2OCH_3$.

8. The compound of claim 7, wherein R^6 and R^7 are independently selected from H and C_1-C_6 alkyl.

9. The compound of claim 1, selected from:

(1E, 4E)-ethyl 2-amino-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[b]azepine-4-carboxylate;

(1E, 4E)-ethyl 2-amino-8-(4-(methoxycarbonyl)phenyl)-3H-benzo[b]azepine-4-carboxylate;

(1E, 4E)-ethyl 2-amino-8-(4-(methylcarbamoyl)phenyl)-3H-benzo[b]azepine-4-carboxylate;

(1E, 4E)-2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[b]azepine-4-carboxamide; and pharmaceutically acceptable salts thereof.

10. A kit for use in treating a TLR7- and/or TLR8-mediated condition, comprising:

a) a first pharmaceutical composition comprising a compound of any one of claims 1 to 9; and

b) optionally instructions for use.

11. A pharmaceutical composition, which comprises a compound as claimed in any one of claims 1 to 9 together with a pharmaceutically acceptable diluent or carrier.

12. A compound according to any one of claims 1 to 9 for use as a medicament.

13. A compound of any one of claims 1 to 9 for use in the treatment of an abnormal cell growth condition in a human or animal.

14. A compound of any one of claims 1 to 9 for use in treating a TLR7- and/or TLR8-mediated condition.


15. A compound of any one of claims 1 to 9 for use in modulating a patient's immune system.

16. Use of a compound of any one of claims 1 to 12 in the manufacture of a medicament for the treatment of an abnormal cell growth condition in a human or animal.

17. Use of a compound of any one of claims 1 to 12 in the manufacture of a medicament for treating a TLR7- and/or TLR8-mediated condition.

18. Use of a compound of any one of claims 1 to 12 in the manufacture of a medicament for modulating a patient's immune system.

1. A compound of the Formula



or solvates, tautomers, or pharmaceutically acceptable salts thereof, wherein:

Y is an aryl or heteroaryl ring, wherein said aryl and heteroaryl rings are substituted with one or more groups independently selected from alkenyl, alkynyl, Br, CN, OH, NR^6R^7, $C(=O)R^8$, $NR^6SO_2R^7$, (C_1-C_6 alkyl)amino, $R^6OC(=O)CH=CH_2$-, SR^6 and SO_2R^6, and wherein said aryl and heteroaryl rings are optionally further substituted with one or more groups independently selected from F, Cl, CF_3, CF_3O-, HCF_2O-, alkyl, heteroalkyl and ArO-;

R^1, R^3 and R^4 are independently selected from H, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl and heteroaryl, wherein said alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted with one or more groups independently selected from alkyl, alkenyl, alkynyl, F, Cl, Br, I, CN, OR^6, NR^6R^7, $C(=O)R^6$,

$C(=O)OR^6$, $OC(=O)R^6$, $C(=O)NR^6R^7$, (C_1-C_6 alkyl)amino, CH_3OCH_2O-, $R^6OC(=O)CH=CH_2$-, $NR^6SO_2R^7$, SR^6 and SO_2R^6,

or R^3 and R^4 together with the atom to which they are attached form a saturated or partially unsaturated carbocyclic ring, wherein said carbocyclic ring is optionally substituted with one or more groups independently selected from alkyl, alkenyl, alkynyl, F, Cl, Br, I, CN, OR^6, NR^6R^7, $C(=O)R^6$, $C(=O)OR^6$, $OC(=O)R^6$, $C(=O)NR^6R^7$, (C_1-C_6 alkyl)amino, CH_3OCH_2O-, $R^6OC(=O)CH=CH_2$-, $NR^6SO_2R^7$, SR^6 and SO_2R^6;

R^2 and R^8 are independently selected from H, OR^6, NR^6R^7, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl and heteroaryl, wherein said alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted with one or more groups independently selected from alkyl, alkenyl, alkynyl, F, Cl, Br, I, CN, OR^6, NR^6R^7, $C(=O)R^6$, $C(=O)OR^6$, $OC(=O)R^6$, $C(=O)NR^6R^7$, (C_1-C_6 alkyl)amino, CH_3OCH_2O-, $R^6OC(=O)CH=CH_2$-, $NR^6SO_2R^7$, SR^6 and SO_2R^6;

R^{5a}, R^{5b}, and R^{5c} are independently H, F, Cl, Br, I, OMe, CH_3, CH_2F, CHF_2 or CF_3; and

R^6 and R^7 are independently selected from H, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl and heteroaryl, wherein said alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted with one or more groups independently selected from alkyl, alkenyl, alkynyl, F, Cl, Br, I, CN, OR^6, NR^6R^7, $C(=O)R^6$, $C(=O)OR^6$, $OC(=O)R^6$, $C(=O)NR^6R^7$, (C_1-C_6 alkyl)amino, CH_3OCH_2O-, $R^6OC(=O)CH=CH_2$-, $NR^6SO_2R^7$, SR^6 and SO_2R^6,

or R^6 and R^7 together with the atom to which they are attached form a saturated or partially unsaturated heterocyclic ring, wherein said heterocyclic ring is optionally substituted with one or more groups independently selected from alkyl, alkenyl, alkynyl, F, Cl, Br, I, CN, OR^6, NR^6R^7, $C(=O)R^6$, $C(=O)OR^6$, $OC(=O)R^6$, $C(=O)NR^6R^7$, (C_1-C_6 alkyl)amino, CH_3OCH_2O-, $R^6OC(=O)CH=CH_2$-, $NR^6SO_2R^7$, SR^6 and SO_2R^6.

2. The compound of claim 1, wherein R^2 is OR^6.

3. The compound of claim 2, wherein R^6 is alkyl.

4. The compound of claim 3, wherein R^6 is ethyl.

5. The compound of claim 1, wherein R^2 is NR^6R^7.

6. The compound of claim 5, wherein R^6 and R^7 are independently H, alkyl or heteroalkyl.

7. The compound of claim 6, wherein R^6 and R^7 are independently H, ethyl, propyl, or $CH_2CH_2OCH_3$.


8. The compound of any one of claims 1 to 7, wherein Y is aryl.


9. The compound of claim 8, wherein said aryl is substituted with $C(=O)R^8$.


10. The compound of claim 9, wherein R^8 is OR^6, NR^6R^7 or heterocycloalkyl.

11. The compound of claim 10, wherein R^6 and R^7 are independently selected from H and alkyl.

12. The compound of claim 10, wherein Y is



,


or


.

13. The compound of any one of claims 1 to 7, wherein Y is CF_2CF_3.

14. The compound of any one of claims 1 to 13, wherein R^1, R^3, R^4, R^{5a}, R^{5b} and R^{5c} are each hydrogen.

15. The compound of claim 1, selected from:

(1E, 4E)-ethyl 2-amino-8-(pyrrolidine-1-carbonyl)-3H-benzo[b]azepine-4-carboxylate;

(1E, 4E)-ethyl 2-amino-8-(4-(methoxycarbonyl)phenyl)-3H-benzo[b]azepine-4-carboxylate;

(1E, 4E)-ethyl 2-amino-8-(4-(methylcarbamoyl)phenyl)-3H-benzo[b]azepine-4-carboxylate;

(1E, 4E)-2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[b]azepine-4-carboxamide; or pharmaceutically acceptable salts thereof.

16. A kit for treating a TLR7- and/or TLR8-mediated condition, comprising:

a) a first pharmaceutical composition comprising a compound of any one of claims 1 to 15; and

b) optionally instructions for use.

17. The kit of claim 16 further comprising (c) a second pharmaceutical composition, wherein the second pharmaceutical composition comprises a second compound for treating a TLR7- and/or TLR8-mediated condition.

18. The kit of claim 17, further comprising instructions for the simultaneous, sequential or separate administration of said first and second pharmaceutical compositions to a patient in need thereof.

19. A pharmaceutical composition, which comprises a compound as claimed in any one of claims 1 to 15 together with a pharmaceutically acceptable diluent or carrier.

20. A composition comprising a compound according to any one of claims 1 to 15 for use as a medicament for treating a TLR7 and/or TLR8-mediated condition in a human or animal.

21. The use of a compound of any one of claims 1 to 15 in the manufacture of a medicament for the treatment of an abnormal cell growth condition in a human or animal.

22. A composition comprising an effective amount of compound according to any one of claims 1 to 15 for treating a TLR7- and/or TLR8-mediated condition.

23. A composition comprising an effective amount of compound according to any one of claims 1 to 15 for modulating a patient's immune system.